Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

347.64USD
22 Jan 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$347.64
Open
--
Day's High
--
Day's Low
--
Volume
753
Avg. Vol
1,226,534
52-wk High
$348.84
52-wk Low
$244.28

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $73,517.84
Shares Outstanding(Mil.): 211.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 33.13 18.18
EPS (TTM): -- -- --
ROI: -- 14.97 33.32
ROE: -- 16.54 17.09

BRIEF-Biogen Responds To Coverage Recommendation By The Canadian Drug Expert Committee (Cdec) For Spinraza

* BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA)

Dec 22 2017

Biogen's Alzheimer's drug fails to meet main goal in mid-stage trial

Dec 21 Biogen Inc said on Thursday one of its drug to treat Alzheimer's disease failed to meet the main goal of a mid-stage trial, sending the drugmaker's shares down 4.3 percent in premarket trading.

Dec 21 2017

BRIEF-Biogen Inc - Results Of Final Analysis On BAN2401 Are Expected During Second Half Of 2018

* ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER’S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT

Dec 21 2017

BRIEF-Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy

* BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY

Dec 19 2017

BRIEF-Biogen Appoints Mark Hernon As SVP, Chief Information Officer

* BIOGEN APPOINTS MARK HERNON AS SVP, CHIEF INFORMATION OFFICER Source text for Eikon: Further company coverage:

Dec 04 2017

BRIEF-Sarissa Capital Management's Alexander​ ‍Denner Buys 30,000 Shares Of Biogen's Common Stock

* SARISSA CAPITAL MANAGEMENT'S ALEXANDER​ ‍DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING Source text: (http://bit.ly/2niyLpi) Further company coverage:

Nov 30 2017

Biogen boosts multiple sclerosis holding with Alkermes license

Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

Nov 27 2017

Biogen boosts multiple sclerosis holding with Alkermes license

Nov 27 Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

Nov 27 2017

BRIEF-Biogen appoints Jeff Capello as executive vice president and chief financial officer

* Appoints Jeff Capello as executive vice president and chief financial officer

Nov 21 2017

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Nov 17 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $148.14 --
Pfizer Inc. (PFE.N) $36.93 --
Novartis AG (NOVN.S) CHF83.92 +0.46
Merck & Co., Inc. (MRK.N) $61.25 --
Roche Holding Ltd. (ROG.S) CHF237.90 +2.10
Roche Holding Ltd. (RO.S) CHF240.20 +1.80
Bayer AG (BAYGn.DE) €108.94 +3.22
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €71.83 +1.00
GlaxoSmithKline plc (GSK.L) 1,373.20 +18.00

Earnings vs. Estimates